ABVC BioPharma (ABVC) SEC Filings: History & Chart

ABVC BioPharma, Inc.(ABVC)

Biotechnology · Fremont, CA

$0.97-0.01 (-1.02%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About ABVC BioPharma, Inc.

ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on creating novel drugs and medical devices to address critical, underserved healthcare requirements across the United States. The company's pipeline includes several key candidates: ABV-1501, currently undergoing Phase I/II clinical trials, is being developed as a combination treatment for triple-negative breast cancer. ABV-1504 has successfully completed Phase II clinical trials for major depressive disorders. ABV-1505 is progressing through Phase II clinical studies for attention deficit hyperactivity disorder (ADHD). ABV-1703 has concluded its Phase I clinical trials for the treatment of pancreatic cancer. ABV-1702 has also finished Phase I clinical investigations for myelodysplastic syndromes. ABV-1601 is in Phase I/II clinical trials, aimed at alleviating depression in individuals with cancer. ABV-1701 Vitargus is in development to treat conditions such as retinal detachment or vitreous hemorrhage. ABVC BioPharma maintains strategic alliances, including a co-development arrangement with Rgene Corporation, alongside collaborative agreements with BioHopeKing Corporation and BioFirst Corporation. The company's headquarters are located in Fremont, California, and it operates as a subsidiary of YuanGene Corporation.

Fremont, CA

18 employees

www.abvcpharma.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Uttam Yashwant Patil

View full financials

Form	Filing Date	Accepted	Document
DEF 14A	Sep 29, 2026	Sep 29, 2026	View filing
PRER14A	Sep 11, 2026	Sep 11, 2026	View filing
8-K	Aug 27, 2026	Aug 27, 2026	View filing
PRER14A	Aug 25, 2026	Aug 25, 2026	View filing
424B4	Aug 17, 2026	Aug 17, 2026	View filing
424B4	Aug 17, 2026	Aug 17, 2026	View filing
424B4	Aug 17, 2026	Aug 17, 2026	View filing
424B4	Aug 17, 2026	Aug 17, 2026	View filing
PRER14A	Aug 12, 2026	Aug 12, 2026	View filing
10-Q	Aug 12, 2026	Aug 12, 2026	View filing
8-K/A	Aug 12, 2026	Aug 12, 2026	View filing
8-K	Aug 4, 2026	Aug 3, 2026	View filing
PRE 14A	Jul 28, 2026	Jul 28, 2026	View filing
8-K	Jul 2, 2026	Jul 2, 2026	View filing
10-Q	May 18, 2026	May 18, 2026	View filing
NT 10-Q	May 15, 2026	May 15, 2026	View filing
POS AM	Mar 27, 2026	Mar 27, 2026	View filing
8-K	Mar 27, 2026	Mar 27, 2026	View filing
DEF 14A	Mar 5, 2026	Mar 5, 2026	View filing
10-K	Mar 3, 2026	Mar 3, 2026	View filing
10-Q/A	Mar 3, 2026	Mar 3, 2026	View filing
8-K	Mar 3, 2026	Mar 3, 2026	View filing
PRE 14A	Feb 5, 2026	Feb 5, 2026	View filing
8-K/A	Jan 16, 2026	Jan 16, 2026	View filing
424B4	Nov 14, 2025	Nov 14, 2025	View filing
424B4	Nov 14, 2025	Nov 14, 2025	View filing
424B4	Nov 14, 2025	Nov 14, 2025	View filing
424B4	Nov 14, 2025	Nov 14, 2025	View filing
8-K	Nov 3, 2025	Nov 3, 2025	View filing
10-Q	Nov 3, 2025	Oct 31, 2025	View filing

SEC Filings

Recent Filings